|
Variables
|
Total
|
Cohort 1
|
Cohort 2
|
P-valuea
|
|---|
|
Number of patients
|
3868
|
1485
|
2383
|
|
Age (year)
|
< 0.001
|
|
< 40
|
445 (11.4)
|
204 (13.8)
|
241 (10.1)
|
|
40–60
|
2589 (67.0)
|
1028 (69.2)
|
1561 (65.5)
|
|
> 60
|
834 (21.6)
|
253 (17.0)
|
581 (24.4)
|
|
Stage
|
< 0.001
|
|
I
|
586 (15.1)
|
206 (13.9)
|
380 (15.9)
|
|
II
|
1553 (40.1)
|
621 (41.8)
|
932 (39.1)
|
|
III
|
831 (21.5)
|
275 (18.5)
|
556 (23.4)
|
|
IV
|
265 (6.8)
|
97 (6.5)
|
168 (7.0)
|
|
Unknown
|
633 (16.4)
|
286 (19.2)
|
347 (14.6)
|
|
Chemotherapy
|
< 0.001
|
|
No
|
1178 (30.4)
|
399 (26.9)
|
779 (32.7)
|
|
Yes
|
2690 (69.5)
|
1086 (73.1)
|
1604 (67.3)
|
|
Chemotherapy Regimens
|
< 0.001
|
|
CMF
|
161 (6.0)
|
142 (13.1)
|
19 (1.2)
|
|
FAC/FEC/AC
|
1930 (71.7)
|
840 (77.4)
|
1090 (67.9)
|
|
AC-T
|
599 (22.3)
|
104 (9.6)
|
495 (30.9)
|
|
Radiotherapy
| | | |
0.03
|
|
No
|
1794 (46.4)
|
722 (48.6)
|
1072 (45.0)
|
|
Yes
|
2074 (53.6)
|
763 (51.4)
|
1311 (55.0)
|
|
Hormonal therapy
|
< 0.001
|
|
No
|
1772 (45.8)
|
770 (51.8)
|
1002 (42.0)
|
|
Yes
|
2096 (54.2)
|
715 (48.1)
|
1381 (58.0)
|
|
Hormonal therapy agent
|
< 0.001
|
|
Tamoxifen
|
1335 (75.2)
|
583 (86.6)
|
752 (68.3)
|
|
Aromatase Inhibitor
|
439 (24.8)
|
90 (13.4)
|
349 (31.7)
|
- CMF Cyclophosphamide, methotrexate, and fluorouracil; FAC Fluorouracil, anthracycline, and cyclophosphamide; FEC Fluorouracil, epirubicin, and cyclophosphamide; AC Anthracycline and cyclophosphamide; AC-T Anthracycline, cyclophosphamide, and taxane
- aChi-square test
